Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report) shares passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.27 and traded as low as $0.25. Adaptimmune Therapeutics shares last traded at $0.26, with a volume of 465,729 shares traded.
Wall Street Analyst Weigh In
ADAP has been the topic of a number of recent analyst reports. Guggenheim lowered their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Wall Street Zen initiated coverage on shares of Adaptimmune Therapeutics in a report on Friday, May 16th. They set a "buy" rating on the stock. Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. Wells Fargo & Company lowered their target price on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 14th. Finally, Barclays reduced their price objective on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1.52.
View Our Latest Report on Adaptimmune Therapeutics
Adaptimmune Therapeutics Price Performance
The company's 50-day moving average is $0.27 and its two-hundred day moving average is $0.42. The company has a debt-to-equity ratio of 4.24, a current ratio of 2.02 and a quick ratio of 1.79. The firm has a market cap of $67.06 million, a P/E ratio of -0.94 and a beta of 2.24.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). The business had revenue of $7.29 million during the quarter, compared to analysts' expectations of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. Sell-side analysts anticipate that Adaptimmune Therapeutics PLC will post -0.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Long Focus Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics by 15.9% in the first quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company's stock valued at $4,680,000 after buying an additional 3,262,294 shares during the period. Two Seas Capital LP boosted its holdings in Adaptimmune Therapeutics by 38.4% in the first quarter. Two Seas Capital LP now owns 20,529,685 shares of the biotechnology company's stock valued at $4,044,000 after acquiring an additional 5,694,539 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock valued at $1,361,000 after acquiring an additional 869,949 shares during the last quarter. Rock Springs Capital Management LP boosted its holdings in Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 58,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Adaptimmune Therapeutics by 334.8% in the first quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company's stock valued at $424,000 after acquiring an additional 1,707,999 shares during the last quarter. Institutional investors and hedge funds own 31.37% of the company's stock.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
